Regeneron pharmaceuticals, inc.REGN.US Overview
REGN Overall Performance
REGN AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
REGN Current Performance
-2.44%
Regeneron pharmaceuticals, inc.
0.67%
Avg of Sector
0.51%
S&P500
REGN Key Information
REGN Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
REGN Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
REGN Profile
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Price of REGN
REGN FAQ
When is REGN's latest earnings report released?
The most recent financial report for Regeneron pharmaceuticals, inc. (REGN) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating REGN's short-term business performance and financial health. For the latest updates on REGN's earnings releases, visit this page regularly.
Where does REGN fall in the P/E River chart?
According to historical valuation range analysis, Regeneron pharmaceuticals, inc. (REGN)'s current price-to-earnings (P/E) ratio is 13.29, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of REGN?
According to the latest financial report, Regeneron pharmaceuticals, inc. (REGN) reported an Operating Profit of 1.08B with an Operating Margin of 29.37% this period, representing a growth of 0.93% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is REGN's revenue growth?
In the latest financial report, Regeneron pharmaceuticals, inc. (REGN) announced revenue of 3.68B, with a Year-Over-Year growth rate of 3.62%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does REGN have?
At the end of the period, Regeneron pharmaceuticals, inc. (REGN) held Total Cash and Cash Equivalents of 2B, accounting for 0.05 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does REGN go with three margins increasing?
In the latest report, Regeneron pharmaceuticals, inc. (REGN) achieved the “three margins increasing” benchmark, with a gross margin of 85.6%%, operating margin of 29.37%%, and net margin of 37.9%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess REGN's profit trajectory and future growth potential.
Is REGN's EPS continuing to grow?
According to the past four quarterly reports, Regeneron pharmaceuticals, inc. (REGN)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 13.24. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of REGN?
Regeneron pharmaceuticals, inc. (REGN)'s Free Cash Flow (FCF) for the period is 925.4M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 378% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of REGN?
The latest valuation data shows Regeneron pharmaceuticals, inc. (REGN) has a Price-To-Earnings (PE) ratio of 13.29 and a Price/Earnings-To-Growth (PEG) ratio of 0.13. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.